Previous 10 | Next 10 |
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Syndax Pharmaceuticals (NASDAQ: SNDX ) : Q2 GAAP EPS of -$0.42 beats by $0.05 . More news on: Syndax Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
WALTHAM, Mass. , Aug. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended ...
WALTHAM, Mass. , Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will parti...
WALTHAM, Mass. , July 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2020 finan...
Syndax Pharmaceuticals (NASDAQ: SNDX ) has appointed Daphne Karydas to succeed Richard P. Shea as CFO, effective July 13, 2020. More news on: Syndax Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
WALTHAM, Mass. , July 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Daphne Karydas as Chief F...
Syndax Pharmaceuticals ( SNDX ) had recently failed a phase 3 study using its drug entinostat plus exemestane, to treat patients with advanced HR+/HER2- breast cancer who had progressed on a non-steroidal aromatase inhibitor. This study failed to meet the primary endpoint of overall survival...
Aurinia Files Application for Voclosporin Approval Aurinia Pharmaceuticals Inc. ( AUPH ) announced that it has submitting a New Drug Application for voclosporin for treating kidney inflammation. The company submitted the data obtained from a global clinical program including the pivotal ...
Gainers: Navidea Biopharmaceuticals (NYSEMKT: NAVB ) +92% . More news on: Navidea Biopharmaceuticals, Inc., XpresSpa Group, Inc., Celsion Corporation, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
14.37%Change Percent:
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...